CO4700426A1 - Ligandos especificos del neuropeptido y1 - Google Patents

Ligandos especificos del neuropeptido y1

Info

Publication number
CO4700426A1
CO4700426A1 CO96022963A CO96022963A CO4700426A1 CO 4700426 A1 CO4700426 A1 CO 4700426A1 CO 96022963 A CO96022963 A CO 96022963A CO 96022963 A CO96022963 A CO 96022963A CO 4700426 A1 CO4700426 A1 CO 4700426A1
Authority
CO
Colombia
Prior art keywords
neuropeptide
leagues
specific
specific leagues
receptors
Prior art date
Application number
CO96022963A
Other languages
English (en)
Inventor
John M Peterson
Charles A Blum
Goulin Cai
Alan Hutchison
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US1995/014472 external-priority patent/WO1996014307A1/en
Application filed by Pfizer filed Critical Pfizer
Publication of CO4700426A1 publication Critical patent/CO4700426A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/02—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LOS COMPUESTOS QUE INTERACCIONAN CON RECEPTORES DE NPY1 E INHIBEN LA ACTIVIDAD DEL NEUROPEPTIDO Y EN ESTOS RECEPTORES SON UTILES EN EL TRATAMIENTO DE TRASTORNOS DE LA ALIMENTACION TALES COMO, POR EJEM PLO, OBESIDAD Y BULIMIA Y CIERTAS ENFERMEDADES CARDIOVASCULARES, TALES COMO, POR EJEMPLO HIPERTEN SION.
CO96022963A 1995-06-07 1996-05-08 Ligandos especificos del neuropeptido y1 CO4700426A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US48497495A 1995-06-07 1995-06-07
US47838395A 1995-06-07 1995-06-07
PCT/US1995/014472 WO1996014307A1 (en) 1994-11-07 1995-11-07 Certain substituted benzylamine derivatives; a new class of neuropeptide y1 specific ligands

Publications (1)

Publication Number Publication Date
CO4700426A1 true CO4700426A1 (es) 1998-12-29

Family

ID=27045885

Family Applications (1)

Application Number Title Priority Date Filing Date
CO96022963A CO4700426A1 (es) 1995-06-07 1996-05-08 Ligandos especificos del neuropeptido y1

Country Status (11)

Country Link
EP (1) EP0833823A1 (es)
JP (1) JPH10507203A (es)
AU (1) AU5578796A (es)
BR (1) BR9609334A (es)
CA (1) CA2220958A1 (es)
CO (1) CO4700426A1 (es)
IL (1) IL117997A0 (es)
MA (1) MA23860A1 (es)
PE (1) PE34297A1 (es)
TR (1) TR199600382A2 (es)
WO (1) WO1996040660A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0915859T3 (da) * 1996-07-23 2003-03-03 Neurogen Corp Visse substituerede benzylaminderivater; en ny klasse af Neuropeptid Y1-specifikke ligander
EP0918761B1 (en) 1996-07-23 2003-05-02 Neurogen Corporation Certain amido- and amino-substituted benzylamine derivatives; a new class of neuropeptite y1 specific ligands
JP2000515151A (ja) * 1996-07-23 2000-11-14 ニューロジェン・コーポレーション 特定の置換ベンジルアミン誘導体；新規クラスの神経ペプチド―ｙ１特異的リガンド
JP2000510164A (ja) * 1997-02-14 2000-08-08 バイエル・コーポレーシヨン 選択的神経ペプチドｙ受容体アンタゴニストとしてのアミド誘導体
US6048900A (en) 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
JP2000510870A (ja) * 1997-02-14 2000-08-22 バイエル・コーポレーシヨン Ｎｐｙ５受容体アンタゴニストとしてのアミド類
US6245817B1 (en) 1997-02-14 2001-06-12 Bayer Corporation NPY5 receptor antagonists and methods for using same
US6420130B1 (en) 1998-12-14 2002-07-16 Aurora Biosciences Corporation Optical molecular sensors for cytochrome P450 activity
WO2000035900A1 (en) * 1998-12-14 2000-06-22 Aurora Biosciences Corporation Optical molecular sensors for cytochrome p450 activity
TW200307539A (en) * 2002-02-01 2003-12-16 Bristol Myers Squibb Co Cycloalkyl inhibitors of potassium channel function
EP1620091B1 (en) 2003-05-05 2010-03-31 Probiodrug AG Inhibitors of glutaminyl cyclase
EP1680120A2 (en) 2003-11-03 2006-07-19 Probiodrug AG Combinations useful for the treatment of neuronal disorders
KR101099206B1 (ko) 2004-02-05 2011-12-27 프로비오드룩 아게 신규한 글루타미닐 시클라제 저해제
EP1834953A1 (en) 2006-03-14 2007-09-19 Ranbaxy Laboratories Limited Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors
WO2008055945A1 (en) 2006-11-09 2008-05-15 Probiodrug Ag 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
CN101668525A (zh) 2007-03-01 2010-03-10 前体生物药物股份公司 谷氨酰胺酰环化酶抑制剂的新用途
EP2865670B1 (en) 2007-04-18 2017-01-11 Probiodrug AG Thiourea derivatives as glutaminyl cyclase inhibitors
EP2475428B1 (en) 2009-09-11 2015-07-01 Probiodrug AG Heterocylcic derivatives as inhibitors of glutaminyl cyclase
US9181233B2 (en) 2010-03-03 2015-11-10 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2011226074B2 (en) 2010-03-10 2015-01-22 Vivoryon Therapeutics N.V. Heterocyclic inhibitors of glutaminyl cyclase (QC, EC 2.3.2.5)
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
DK2686313T3 (en) 2011-03-16 2016-05-02 Probiodrug Ag Benzimidazole derivatives as inhibitors of glutaminyl cyclase
DK3461819T3 (da) 2017-09-29 2020-08-10 Probiodrug Ag Inhibitorer af glutaminylcyklase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845221A (en) * 1988-04-15 1989-07-04 American Home Products Corporation Serotonergic substituted piperazinyl tetralins
DE69033100T2 (de) * 1989-04-22 2000-01-05 Wyeth John & Brother Ltd Piperazin-Derivate

Also Published As

Publication number Publication date
MX9709980A (es) 1998-03-29
CA2220958A1 (en) 1996-12-19
PE34297A1 (es) 1997-09-24
BR9609334A (pt) 1999-05-25
JPH10507203A (ja) 1998-07-14
EP0833823A1 (en) 1998-04-08
IL117997A0 (en) 1996-10-31
MA23860A1 (fr) 1996-12-31
AU5578796A (en) 1996-12-30
WO1996040660A1 (en) 1996-12-19
TR199600382A2 (tr) 1996-12-21

Similar Documents

Publication Publication Date Title
CO4700426A1 (es) Ligandos especificos del neuropeptido y1
UY28442A1 (es) Compuestos de indazol 3,5-disustituidos, composiciones farmaceuticas y métodos para intervenir en o inhibir la proliferacion celular
PA8493701A1 (es) Compuestos para tratar la obesidad
YU47525B (sh) Zeleno staklo za apsorpciju infracrvenog i ultravioletnog zračenja i automobilsko staklo izradjeno od istog
GT199900067A (es) Nuevas 4-fenilpiperidinas para el tratamiento dedermatosis prurìtica.
ES2097341T3 (es) Indoles sustituidos como farmacos para el tratamiento del sida.
SV2004000061A (es) Moduladores del receptor glucocorticoide ref. 10118 amag/bb
ES2153469T3 (es) Compuestos con propiedades para liberar la hormona del crecimiento.
ES2170141T3 (es) 4-aminoderivados del acido micofenolico con actividad inmunosupresora.
ES2154674T3 (es) Derivados de 1,5-benzodiacepinas con actividad antagonista o agonista de cck.
GT199900070A (es) Derivados de isotiazol, utiles como agentes anticancerosos.
EA200100780A1 (ru) Антагонисты tweak и рецептора tweak и их использование для лечения иммунологических заболеваний
ES2165878T3 (es) Utilizacion del modafinil para el tratamiento de las apneas del sueño y trastornos de ventilacion de origen central.
ES2058306T3 (es) Tetralinas substituidas, cromanos y compuestos relacionados en el tratamiento del asma, artritis y enfermedades relacionadas.
UA29466C2 (uk) Фармацевтична композиція з антипухлинною активністю
ES2121949T3 (es) Derivados de benceno 1,2,4-trioxigenados utiles como antagonistas de leucotrienos.
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
TR199700956T1 (xx) Indazolkarboksamidler.
MX9205358A (es) Compuestos para tratar enfermedades relacionadas con leucotrieno.
ES2170798T3 (es) Benzopiranos y su uso como agentes terapeuticos.
ES2063747T3 (es) Nuevos benzotiofenos que tienen actividad antialergica, asi como nuevos benzotiofenos y otros benzotiofenos seleccionados que tienen actividad para el tratamiento del sindrome de malestar respiratorio agudo.
ES2100689T3 (es) Asociacion sinergizante que tiene un efecto antagonista de los receptores nk1 y nk2.
PT684816E (pt) Composicoes antagonistas do receptor da 5-ht2 uteis no tratamento de doencas venosas
ES2163220T3 (es) Dioxacicloalcan-8-ona.
ES2038642T3 (es) Tratamiento dermico de enfermedades vermiculares del gato con pracicuantel.